AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02294266
Drug: Mephedrone and alcohol
RxNorm normalized name: Alcohol
DrugBank: Mephedrone (DB13108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose mephedrone~Single oral dose alcohol
Trial: NCT02294266
Drug: Mephedrone
RxNorm normalized name: Mephedrone
DrugBank: Mephedrone (DB13108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose mephedrone
Trial: NCT02294266
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose alcohol
Trial: NCT00833326
Drug: Docetaxel, mitotic inhibitor; intravenous
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: multiple dose, single schedule
Trial: NCT03386526
Drug: APG-1387 for Injection
RxNorm normalized name: APGA
DrugBank: APG-1387 (DB16095)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose cohorts, 30 minute IV infusion, once weekly for 3 weeks of a 21-day cycle
Trial: NCT00005649
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT05624853
Drug: pregabalin sustained release tablet
RxNorm normalized name: pregabalin Extended Release Oral Tablet
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin sustained release tablet 150mg qd for 8weeks
Trial: NCT05624853
Drug: pregabalin immediate release capsule
RxNorm normalized name: pregabalin Extended Release Oral Tablet
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin immediate release capsule 75mg bid for 8weeks
Trial: NCT00246402
Drug: Acipimox
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00047762
Drug: Erlotinib (aka Tarceva or OSI-774)
RxNorm normalized name: erlotinib Oral Tablet [Tarceva]
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00047762
Drug: Bevacizumab (aka Avastin or Rhu MAb VEGF)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00118950
Drug: Placebo-Metformin.
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet Placebo (corresponding to 500 mg Metformin). Dosage: 2 tablets two times daily. Duration: Four months.
Trial: NCT01615627
Drug: HypotonicTreprostinil Solution
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hypotonic Treprostinil Solution
Trial: NCT01615627
Drug: Eutonic Treprostinil Solution
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eutonic Treprostinil Solution
Trial: NCT04096157
Drug: Isavuconazonium sulfate IV
RxNorm normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous (IV) via nasogastric (NG) tube
Trial: NCT04096157
Drug: Isavuconazonium sulfate capsules
RxNorm normalized name: Isavuconazonium Sulfate Capsules
DrugBank: Isavuconazonium (DB06636)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral
Trial: NCT03549312
Drug: Genvoya
RxNorm normalized name: Genvoya
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Switching to Genvoya for 48 weeks in patients with HIV/HCV co-infection and stably suppressed HIV RNA, prior to starting HCV treatment, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA \< 50 copies/mL at weeks 4, 12, 24, 36 and 48.
Trial: NCT03549312
Drug: Epclusa
RxNorm normalized name: Epclusa
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HCV therapy with direct-acting-antiviral therapy with Epclusa in HIV-HCV co-infected patients with suppressed HIV RNA, receiving methadone as opioid substitution therapy.~Plasma HCV RNA viral load at weeks 12, 24, 36, 48, 72 and 96.
Trial: NCT03549312
Drug: Biktarvy
RxNorm normalized name: Biktarvy
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Switching to Biktarvy for 48 weeks in patients with HIV previously treated with Genvoya, stably supressed HIV RNA, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA \< 50 copies/mL at weeks 52, 60, 72, 84 and 96.
Trial: NCT02196714
Drug: Glycopyrronium and Formoterol Fumarate (GFF) Dose 1
RxNorm normalized name: formoterol / glycopyrronium Metered Dose Inhaler
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
Trial: NCT02196714
Drug: Glycopyrronium and Formoterol Fumarate (GFF) Dose 2
RxNorm normalized name: formoterol / glycopyrronium Metered Dose Inhaler
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
Trial: NCT02196714
Drug: Glycopyrronium (GP) Dose 1
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
Trial: NCT02196714
Drug: Glycopyrronium (GP) Dose 2
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
Trial: NCT00118950
Drug: Placebo-Repaglinide.
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet Placebo (corresponding to 1 mg Repaglinide). Dosage: 2 tablets three times daily. Duration: Four months.
Trial: NCT02802098
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics.
Trial: NCT02802098
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
Trial: NCT02271425
Drug: Evacetrapib Tablet
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02271425
Drug: Evacetrapib Intravenous
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT01001832
Drug: Intravenous (IV) abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.
Trial: NCT01001832
Drug: Subcutaneous (SC) abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks
Trial: NCT02425930
Drug: S-1+Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1
Trial: NCT00256451
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/day for two days prior to the alcohol challenge session
Trial: NCT00216372
Drug: Lanreotide (microparticle formulation)
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.
Trial: NCT00568945
Drug: Capadenoson (BAY68-4986)
RxNorm normalized name: Capadenoson
DrugBank: Capadenoson (DB16118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg BAY68-4986 for five days
Trial: NCT02425683
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 120 mg or 160 mg by mouth each day for first 21 days of each 28-day cycle, for maximum of 6 cycles
Trial: NCT00747214
Drug: CRx-102
RxNorm normalized name: CRx-119
DrugBank: CRx-119 (DB05688)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00508976
Drug: Injected bupivacaine post-operatively
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation, and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Trial: NCT00508976
Drug: Streamed bupivacaine versus streamed normal saline
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 30ml of 0.9% normal saline divided equally and injected prior to port site incisions, then 10ml of 0.5% bupivacaine streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Trial: NCT00508976
Drug: Aerosolized bupivacaine versus aerosolized saline
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.5% bupivacaine aerosolized into coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Trial: NCT00508976
Drug: Injected lidocaine pre-incision vs saline pre-incision
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 30ml of 1% lidocaine divided equally and injected prior to port site incisions, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Trial: NCT03423264
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin taken as follows:~Day 1 (evening): 600 mg Day 2 (morning): 600 mg Day 2 (evening): 600 mg Day 3 (morning): 600 mg Day 3 (evening): 900 mg Day 4 (morning): 900 mg Day 4 (evening): 900 mg Day 5 (morning): 900 mg Day 5 (noon): 900 mg Day 5 (evening): 900 mg
Trial: NCT01013285
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02861261
Drug: 1. Berberine hydrochloride tablets ; 2. ProMetS probiotics powder
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal ;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night
Trial: NCT00465179
Drug: Sunitinib Malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg by mouth daily for 4 weeks, then 2 weeks off.
Trial: NCT01933594
Drug: Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RMD administered over 4 hours via an intravenous (IV) catheter.
Trial: NCT01933594
Drug: Placebo for Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo for RMD administered over 4 hours via an IV catheter.
Trial: NCT03012646
Drug: Inhaled Treprostinil
RxNorm normalized name: treprostinil Inhalation Solution
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inhaled treprostinil (6 mcg/breath) administered four times daily
Trial: NCT02861261
Drug: 1. Berberine placebo tablets ; 2. ProMetS probiotics powder
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. 6 pills of Berberine placebo tablets administered twice a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night
Trial: NCT01498289
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/m\^2, IV over 30 minutes on Day 1,8 of each 21 day cycle.
Trial: NCT01498289
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 65 mg/m\^2, IV over 90 minutes on Days 1 \& 8 of every 21 day cycle.
Trial: NCT01498289
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
Trial: NCT02805608
Drug: Injection of 68Ga-NOTA-AE105
RxNorm normalized name: sodium bicarbonate Injection [Neut brand of sodium bicarbonate]
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One injection intravenously of 68Ga-NOTA-AE105
Trial: NCT02805608
Drug: Injection of 18F-FDG
RxNorm normalized name: (18F)-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One injection intravenously of 18F-FDG
Trial: NCT02954068
Drug: IV Oxytocin + IM placebo
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02954068
Drug: IM Oxytocin + IV placebo
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00833755
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
Trial: NCT02182557
Drug: Ketotifen Fumarate Dry Syrup
RxNorm normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02182557
Drug: Ketotifen Fumarate Dry Syrup placebo
RxNorm normalized name: Ketotifen Fumarate
DrugBank: Ketotifen (DB00920)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03797079
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the negative aspiration for blood, a bolus dose of 15 ml 0.125% plain bupivacaine will be injected in the catheter, followed by a continuous infusion of 0.25% plain bupivacaine at the rate of 0.1 ml/kg/h for 48 hours
Trial: NCT01292408
Drug: Hydrochloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800 mg per os once, and then 400 mg per day
Trial: NCT00244439
Drug: Permethrin 1%
RxNorm normalized name: PERMETHRIN 1% LIQUID,TOP
DrugBank: Permethrin (DB04930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 minute application
Trial: NCT00471497
Drug: nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
Trial: NCT00471497
Drug: imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
Trial: NCT04163874
Drug: Fiasp
RxNorm normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fiasp Insulin delivered in a basal-bolus manner.
Trial: NCT04163874
Drug: Pramlintide Acetate
RxNorm normalized name: Pramlintide Acetate
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pramlintide delivered in a basal-bolus manner with a fixed ratio with insulin.
Trial: NCT00981617
Drug: ALKS33 (RDC-0313) (1 mg)
RxNorm normalized name: rh-RdCVF
DrugBank: FOV 2501 (DB17886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
Trial: NCT00981617
Drug: ALKS33 (RDC-0313) (2.5 mg)
RxNorm normalized name: rh-RdCVF
DrugBank: FOV 2501 (DB17886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
Trial: NCT00981617
Drug: ALKS33 (RDC-0313) (10 mg)
RxNorm normalized name: rh-RdCVF
DrugBank: FOV 2501 (DB17886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
Trial: NCT00605020
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00605020
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01990118
Drug: Neoral
RxNorm normalized name: Neoral
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral® capsule containing 25mg or 100mg cyclosporine
Trial: NCT01990118
Drug: Gengraf® capsule containing 25mg or 100mg cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transplant patients who were stable on Neoral were converted to Gengraf
Trial: NCT04578782
Drug: OnabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: BOTOX contains onabotulinumtoxinA, an acetylcholine release inhibitor and a neuromuscular blocking agent available in the lyophilized form of purified clostridium botulinum toxin type A, suitable for injection, for intramuscular, intradetrusor, or intradermal use. The recommended dilution is 100 Units/2 mL, with a final concentration of 5 Units per 0.1 mL. The recommended dose for treating chronic migraine is 155 Units administered intramuscularly using a sterile 30-gauge, needle as 0.1 mL (5 Units) injections per each site.
Trial: NCT01387269
Drug: Anamorelin HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Anamorelin (DB06645)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Anamorelin HCl will be orally administered daily at least one hour before meal
Trial: NCT00236717
Drug: Topiramate; Carbamazepine; Valproate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02939547
Drug: Hydroxypropyl-beta-cyclodextrin
RxNorm normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used in the treatment of Niemann-Pick Disease C1 ( NPC1)
Trial: NCT02041520
Drug: omega 3 fatty acids
RxNorm normalized name: Omega 3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
Trial: NCT00096811
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 1 mg once daily. Until subject achieves a complete response or until ETV approved and marketed in a given country.
Trial: NCT00862628
Drug: Rebamipide
RxNorm normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 100mg tid, 4 or 8 weeks
Trial: NCT02373410
Drug: Umbilicus Bupivacaine
RxNorm normalized name: Umbilicus rupestris extract
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
Trial: NCT02373410
Drug: Lowest rib margin Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
Trial: NCT02373410
Drug: Xiphoid Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
Trial: NCT02373410
Drug: Nipple Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
Trial: NCT02861261
Drug: 1. Berberine hydrochloride tablets; 2. Probiotics placebo powder
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal;~2. 2 strips of probiotics placebo powder administered orally every night
Trial: NCT01512888
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously (IV).
Trial: NCT01222299
Drug: bepotastine besilate nasal product - low dose
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sterile nasal product